Geron Corp. (NASDAQ:GERN)‘s stock had its “neutral” rating restated by investment analysts at BTIG Research in a research note issued to investors on Tuesday.

Several other research firms have also issued reports on GERN. Zacks Investment Research raised shares of Geron Corp. from a “hold” rating to a “strong-buy” rating and set a $3.00 price target on the stock in a research report on Friday, August 5th. FBR & Co dropped their price objective on shares of Geron Corp. from $6.00 to $5.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 13th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $5.00 price objective (down from $10.00) on shares of Geron Corp. in a research report on Tuesday, September 13th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Geron Corp. presently has a consensus rating of “Buy” and an average price target of $5.00.

Shares of Geron Corp. (NASDAQ:GERN) traded up 4.50% during mid-day trading on Tuesday, hitting $2.09. 1,211,719 shares of the stock traded hands. The firm has a market capitalization of $332.60 million, a P/E ratio of 261.25 and a beta of 2.63. The company’s 50 day moving average is $2.64 and its 200 day moving average is $2.80. Geron Corp. has a one year low of $1.84 and a one year high of $5.30.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/geron-corp-gern-given-neutral-rating-at-btig-research.html

Geron Corp. (NASDAQ:GERN) last posted its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.02. Geron Corp. had a net margin of 3.39% and a return on equity of 0.89%. The firm had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.38 million. During the same period in the prior year, the firm posted ($0.06) earnings per share. The company’s quarterly revenue was down 15.9% compared to the same quarter last year. On average, equities analysts expect that Geron Corp. will post ($0.23) EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in GERN. Bank of Montreal Can acquired a new position in Geron Corp. during the second quarter valued at approximately $108,000. Creative Planning increased its position in Geron Corp. by 3.5% in the second quarter. Creative Planning now owns 59,700 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 2,000 shares during the period. Panagora Asset Management Inc. increased its position in Geron Corp. by 32.9% in the first quarter. Panagora Asset Management Inc. now owns 1,823,587 shares of the biopharmaceutical company’s stock valued at $5,325,000 after buying an additional 451,440 shares during the period. LPL Financial LLC increased its position in Geron Corp. by 81.0% in the first quarter. LPL Financial LLC now owns 35,750 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 16,000 shares during the period. Finally, Metropolitan Life Insurance Co. NY increased its position in Geron Corp. by 0.7% in the first quarter. Metropolitan Life Insurance Co. NY now owns 113,715 shares of the biopharmaceutical company’s stock valued at $332,000 after buying an additional 839 shares during the period. Institutional investors and hedge funds own 38.09% of the company’s stock.

Geron Corp. Company Profile

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology.

5 Day Chart for NASDAQ:GERN

Receive News & Ratings for Geron Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Corp. and related companies with MarketBeat.com's FREE daily email newsletter.